References
- Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 2021;23:1231-51.
- Leu S, von Felten S, Frank S, Vassella E, Vajtai I, Taylor E, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol 2013;15:469-79.
- Tamimi AF, Juweid M. Epidemiology and Outcome of Glioblastoma. Brisbane: Exon Publications; 2017. p. 143-53.
- Bajwa MH, Khalid MU, Shah MM, Shamim MS, Laghari AA, Akhunzada NZ, et al. Treatment patterns of glioma in Pakistan: An epidemiological perspective. J Pak Med Assoc 2022;72:S34-9.
- Balça-Silva J, Matias D, do Carmo A, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. Semin Cancer Biol 2019;58:130-41.
- Aquilanti E, Miller J, Santagata S, Cahill DP, Brastianos PK. Updates in prognostic markers for gliomas. Neuro Oncol 2018;20:vii17-26.
- Enam SA, Shah MM, Bajwa MH, Khalid MU, Bakhshi SK, Baig E, et al. The Pakistan brain tumour epidemiology study. J Pak Med Assoc 2022;72:S4-11.
- Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011;13:649-59.
- Ruff MW, Buckner JC, Johnson DR, Van Den Bent MJ, Geurts M. Neuro-oncology clinical debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. Neuro Oncol Pract 2019;6:17-21.
- Wick W, Winkler F. Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas. Cancer 2018;124:2674-6.
- Lu VM, Goyal A, Quinones-Hinojosa A, Chaichana KL. Updated incidence of neurological deficits following insular glioma resection: A systematic review and meta-analysis. Clin Neurol Neurosurg 2019;177:20-6.
- Sanai N, Berger MS. Extent of resection influences outcomes for patients with gliomas. Rev Neurol (Paris) 2011;167:648-54.
- Yamaguchi S, Kobayashi H, Terasaka S, Ishii N, Ikeda J, Kanno H, et al. The impact of extent of resection and histological subtype on the outcome of adult patients with high-grade gliomas. Jpn J Clin Oncol 2012;42:270-7.
- Cheng HB, Yue W, Xie C, Zhang RY, Hu SS, Wang Z. IDH1 mutation is associated with improved overall survival in patients with glioblastoma: A meta-analysis. Tumor Biol 2013;34:3555-9.
- Zhao J, Ma W, Zhao H. Loss of heterozygosity 1p/19q and survival in glioma: A meta-analysis. Neuro Oncol 2014;16:103-12.